Background: The most common bladder cancer (BC) histotype is pure urothelial carcinoma (UC), which may undergo divergent differentiation in some cases. Variant histology (VH) presents along variable morphologies, either single or combined between them or with pure UC. From a clinical standpoint, the vast majority of BC is diagnosed at non-invasive or minimally invasive stages, namely as non-muscle invasive BC (NMIBC). There is a wide range of therapeutic options for patients with NMIBC, according to their clinical and pathological features. However, current risk stratification models do not show optimal effectiveness. Evidence from the literature suggests that VH has peculiar biological features, and may be associated with poorer survival outcomes compared to pure UC. Summary: In order to describe the biological features and prognostic/predictive role of VH in NMIBC, and to discuss current treatment options, we performed a systematic literature search through multiple databases (PubMed/Medline, Google Scholar) for relevant articles according to the following terms, single and/or in combination: “non-muscle invasive bladder cancer,” “variant histology,” “micropapillary variant,” “glandular differentiation,” “squamous differentiation,” “nested variant,” “plasmacytoid variant,” and “sarcomatoid variant.” We extracted 99 studies including original articles, reviews, and systematic reviews, and subsequently analyzed data from 16 studies reporting on the outcome of NMIBC with VH. We found that the relative rarity of these forms as well as the heterogeneity in study populations and therapeutic protocols results in conflicting findings overall. Key Messages: The presence of VH should be taken into account when counseling a patient with NMIBC, since it may upgrade the disease to high-risk tumor and thus warrant a more aggressive treatment.

1.
IARC-WHO. Global Cancer Observatory. Available from: gco.iarc.frhttps://gco.iarc.fr (accessed October 2020).
2.
Bray
F
,
Ferlay
J
,
Soerjomataram
I
,
Siegel
RL
,
Torre
LA
,
Jemal
A
.
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
.
CA Cancer J Clin
.
2018
;
68
(
6
):
394
424
. .
3.
Moschini
M
,
Karnes
RJ
,
Sharma
V
,
Gandaglia
G
,
Fossati
N
,
Dell'Oglio
P
, et al
Patterns and prognostic significance of clinical recurrences after radical cystectomy for bladder cancer: a 20-year single center experience
.
Eur J Surg Oncol
.
2016
;
42
(
5
):
735
43
. .
4.
Lopez-Beltran
A
,
Cheng
L
.
Histologic variants of urothelial carcinoma: differential diagnosis and clinical implications
.
Hum Pathol
.
2006
;
37
(
11
):
1371
88
. .
5.
Babjuk
M
,
Burger
M
,
Compérat
EM
,
Gontero
P
,
Mostafid
AH
,
Palou
J
, et al
European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) – 2019 Update
.
Eur Urol
.
2019
;
76
(
5
):
639
57
. .
6.
Siegel
RL
,
Miller
KD
,
Jemal
A
.
Cancer Statistics, 2017
.
CA Cancer J Clin
.
2017
;
67
(
1
):
7
30
. .
7.
Abdollah
F
,
Gandaglia
G
,
Thuret
R
,
Schmitges
J
,
Tian
Z
,
Jeldres
C
, et al
Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis
.
Cancer Epidemiol
.
2013
;
37
(
3
):
219
25
. .
8.
Xylinas
E
,
Rink
M
,
Robinson
BD
,
Lotan
Y
,
Babjuk
M
,
Brisuda
A
, et al
Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy
.
Eur J Cancer
.
2013
;
49
(
8
):
1889
97
. .
9.
Shah
RB
,
Montgomery
JS
,
Montie
JE
,
Kunju
LP
.
Variant (divergent) histologic differentiation in urothelial carcinoma is under-recognized in community practice: impact of mandatory central pathology review at a large referral hospital
.
Urol Oncol
.
2013
;
31
(
8
):
1650
5
. .
10.
Shapur
NK
,
Katz
R
,
Pode
D
,
Shapiro
A
,
Yutkin
V
,
Pizov
G
, et al
Is radical cystectomy mandatory in every patient with variant histology of bladder cancer
.
Rare Tumors
.
2011
;
3
(
2
):
e22
. .
11.
Erdemir
F
,
Tunc
M
,
Ozcan
F
,
Parlaktas
BS
,
Uluocak
N
,
Kilicaslan
I
, et al
The effect of squamous and/or glandular differentiation on recurrence, progression and survival in urothelial carcinoma of bladder
.
Int Urol Nephrol
.
2007
;
39
(
3
):
803
7
. .
12.
Mitra
AP
,
Bartsch
CC
,
Bartsch
G
 Jr
,
Miranda
G
,
Skinner
EC
,
Daneshmand
S
.
Does presence of squamous and glandular differentiation in urothelial carcinoma of the bladder at cystectomy portend poor prognosis? An intensive case-control analysis
.
Urol Oncol
.
2014
;
32
(
2
):
117
27
. .
13.
Gellert
LL
,
Warrick
J
,
Al-Ahmadie
HA
.
Urothelial carcinoma with squamous differentiation – the pathologists' perspective
.
Urol Oncol
.
2015
;
33
(
10
):
437
43
. .
14.
Wasco
MJ
,
Daignault
S
,
Zhang
Y
,
Kunju
LP
,
Kinnaman
M
,
Braun
T
, et al
Urothelial carcinoma with divergent histologic differentiation (mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection
.
Urology
.
2007
;
70
(
1
):
69
74
. .
15.
Cai
T
,
Tiscione
D
,
Verze
P
,
Pomara
G
,
Racioppi
M
,
Nesi
G
, et al
Concordance and clinical significance of uncommon variants of bladder urothelial carcinoma in transurethral resection and radical cystectomy specimens
.
Urology
.
2014
;
84
(
5
):
1141
6
. .
16.
Humphrey
PA
,
Moch
H
,
Cubilla
AL
,
Ulbright
TM
,
Reuter
VE
.
The 2016 WHO classification of tumours of the urinary system and male genital organs-part b: prostate and bladder tumours
.
Eur Urol
.
2016
;
70
(
1
):
106
19
. .
17.
Ploeg
M
,
Aben
KK
,
Hulsbergen-van de Kaa
CA
,
Schoenberg
MP
,
Witjes
JA
,
Kiemeney
LA
.
Clinical epidemiology of nonurothelial bladder cancer: analysis of the Netherlands Cancer Registry
.
J Urol
.
2010
;
183
(
3
):
915
20
. .
18.
Chalasani
V
,
Chin
JL
,
Izawa
JI
.
Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer
.
Can Urol Assoc J
.
2009
;
3
(
6 Suppl 4
):
S193
8
. .
19.
Lee
YJ
,
Moon
KC
,
Jeong
CW
,
Kwak
C
,
Kim
HH
,
Ku
JH
.
Impact of squamous and glandular differentiation on oncologic outcomes in upper and lower tract urothelial carcinoma
.
PLoS One
.
2014
;
9
(
9
):
e107027
. .
20.
Taylor
J
,
Becher
E
,
Steinberg
GD
.
Update on the guideline of guidelines: non-muscle-invasive bladder cancer
.
BJU Int
.
2020
;
125
(
2
):
197
205
. .
21.
Moschini
M
,
D'Andrea
D
,
Korn
S
,
Irmak
Y
,
Soria
F
,
Compérat
E
, et al
Characteristics and clinical significance of histological variants of bladder cancer
.
Nat Rev Urol
.
2017
;
14
(
11
):
651
68
. .
22.
Billis
A
,
Schenka
AA
,
Ramos
CC
,
Carneiro
LT
,
Araújo
V
.
Squamous and/or glandular differentiation in urothelial carcinoma: prevalence and significance in transurethral resections of the bladder
.
Int Urol Nephrol
.
2001
;
33
(
4
):
631
3
. .
23.
Black
PC
,
Brown
GA
,
Dinney
CP
.
The impact of variant histology on the outcome of bladder cancer treated with curative intent
.
Urol Oncol
.
2009
;
27
(
1
):
3
7
. .
24.
Baumeister
P
,
Zamboni
S
,
Mattei
A
,
Antonelli
A
,
Simeone
C
,
Mordasini
L
, et al
Histological variants in non-muscle invasive bladder cancer
.
Transl Androl Urol
.
2019
;
8
(
1
):
34
8
. .
25.
Liberati
A
,
Altman
DG
,
Tetzlaff
J
,
Mulrow
C
,
Gøtzsche
PC
,
Ioannidis
JP
, et al
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration
.
PLoS Med
.
2009
;
6
(
7
):
e1000100
. .
26.
Meeks
JJ
,
Al-Ahmadie
H
,
Faltas
BM
,
Taylor
JA
 3rd
,
Flaig
TW
,
DeGraff
DJ
, et al
Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes
.
Nat Rev Urol
.
2020
;
17
(
5
):
259
70
. .
27.
Warrick
JI
,
Sjödahl
G
,
Kaag
M
,
Raman
JD
,
Merrill
S
,
Shuman
L
, et al
Intratumoral heterogeneity of bladder cancer by molecular subtypes and histologic variants
.
Eur Urol
.
2019
;
75
(
1
):
18
22
. .
28.
Mukherjee
N
,
Wheeler
KM
,
Svatek
RS
.
Bacillus Calmette-Guérin treatment of bladder cancer: a systematic review and commentary on recent publications
.
Curr Opin Urol
.
2019
;
29
(
3
):
181
8
.
29.
Cancer Genome Atlas Research Network
.
Comprehensive molecular characterization of urothelial bladder carcinoma
.
Nature
.
2014
;
507
(
7492
):
315
22
. .
30.
Guo
CC
,
Majewski
T
,
Zhang
L
,
Yao
H
,
Bondaruk
J
,
Wang
Y
, et al
Dysregulation of EMT drives the progression to clinically aggressive sarcomatoid bladder cancer
.
Cell Rep
.
2019
;
27
(
6
):
1781
e4
. .
31.
Warrick
JI
,
Kaag
M
,
Raman
JD
,
Chan
W
,
Tran
T
,
Kunchala
S
, et al
FOXA1 and CK14 as markers of luminal and basal subtypes in histologic variants of bladder cancer and their associated conventional urothelial carcinoma
.
Virchows Arch
.
2017
;
471
(
3
):
337
45
. .
32.
Willis
DL
,
Porten
SP
,
Kamat
AM
.
Should histologic variants alter definitive treatment of bladder cancer?
Curr Opin Urol
.
2013
;
23
(
5
):
435
43
. .
33.
Kamat
AM
,
Dinney
CP
,
Gee
JR
,
Grossman
HB
,
Siefker-Radtke
AO
,
Tamboli
P
, et al
Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients
.
Cancer
.
2007
;
110
(
1
):
62
7
. .
34.
Matulay
JT
,
Narayan
VM
,
Kamat
AM
.
Clinical and genomic considerations for variant histology in bladder cancer
.
Curr Oncol Rep
.
2019
;
21
(
3
):
23
. .
35.
Abd El-Latif
A
,
Watts
KE
,
Elson
P
,
Fergany
A
,
Hansel
DE
.
The sensitivity of initial transurethral resection or biopsy of bladder tumor(s) for detecting bladder cancer variants on radical cystectomy
.
J Urol
.
2013
;
189
(
4
):
1263
7
. .
36.
Abufaraj
M
,
Shariat
SF
,
Foerster
B
,
Pozo
C
,
Moschini
M
,
D'Andrea
D
, et al
Accuracy and prognostic value of variant histology and lymphovascular invasion at transurethral resection of bladder
.
World J Urol
.
2018
;
36
(
2
):
231
40
. .
37.
Burger
M
,
Kamat
AM
,
McConkey
D
.
Does variant histology change management of non-muscle-invasive bladder cancer?
Eur Urol Oncol
.
2019
;
S2588-9311
(
19
):
30093
8
.
38.
Jozwicki
W
,
Domaniewski
J
,
Skok
Z
,
Wolski
Z
,
Domanowska
E
,
Jozwicka
G
.
Usefulness of histologic homogeneity estimation of muscle-invasive urinary bladder cancer in an individual prognosis: a mapping study
.
Urology
.
2005
;
66
(
5
):
1122
6
. .
39.
Deuker
M
,
Martin
T
,
Stolzenbach
F
,
Rosiello
G
,
Collà Ruvolo
C
,
Nocera
L
, et al
Bladder cancer: a comparison between non-urothelial variant histology and urothelial carcinoma across all stages and treatment modalities
.
Clin Genitourin Cancer
.
2020
;
S1558-7673
(
20
):
30171
3
.
40.
Porten
SP
,
Willis
D
,
Kamat
AM
.
Variant histology: role in management and prognosis of nonmuscle invasive bladder cancer
.
Curr Opin Urol
.
2014
;
24
(
5
):
517
23
. .
41.
Weizer
AZ
,
Wasco
MJ
,
Wang
R
,
Daignault
S
,
Lee
CT
,
Shah
RB
.
Multiple adverse histological features increase the odds of under staging T1 bladder cancer
.
J Urol
.
2009
;
182
(
1
):
59
65
. .
42.
Willis
DL
,
Fernandez
MI
,
Dickstein
RJ
,
Parikh
S
,
Shah
JB
,
Pisters
LL
, et al
Clinical outcomes of cT1 micropapillary bladder cancer
.
J Urol
.
2015
;
193
(
4
):
1129
34
. .
43.
Shanks
JH
,
Iczkowski
KA
.
Divergent differentiation in urothelial carcinoma and other bladder cancer subtypes with selected mimics
.
Histopathology
.
2009
;
54
(
7
):
885
900
. .
44.
Hansel
DE
,
Amin
MB
,
Comperat
E
,
Cote
RJ
,
Knüchel
R
,
Montironi
R
, et al
A contemporary update on pathology standards for bladder cancer: transurethral resection and radical cystectomy specimens
.
Eur Urol
.
2013
;
63
(
2
):
321
32
. .
45.
Kamat
AM
,
Gee
JR
,
Dinney
CP
,
Grossman
HB
,
Swanson
DA
,
Millikan
RE
, et al
The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma
.
J Urol
.
2006
;
175
(
3 Pt 1
):
881
5
. .
46.
Raspollini
MR
,
Montironi
R
,
Mazzucchelli
R
,
Cimadamore
A
,
Cheng
L
,
Lopez-Beltran
A
.
pT1 high-grade bladder cancer: histologic criteria, pitfalls in the assessment of invasion, and substaging
.
Virchows Arch
.
2020
;
477
(
1
):
3
16
. .
47.
Wright
JL
,
Black
PC
,
Brown
GA
,
Porter
MP
,
Kamat
AM
,
Dinney
CP
, et al
Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder
.
J Urol
.
2007
;
178
(
6
):
2302
7
. .
48.
Koch
GE
,
Luckenbaugh
AN
,
Chang
SS
.
High-risk non-muscle invasive bladder cancer: selecting the appropriate patient for timely cystectomy
.
Urology
.
2020
;
S0090-4295
(
20
):
30573
2
.
49.
Miyake
M
,
Gotoh
D
,
Shimada
K
,
Tatsumi
Y
,
Nakai
Y
,
Anai
S
, et al
Exploration of risk factors predicting outcomes for primary T1 high-grade bladder cancer and validation of the Spanish Urological Club for Oncological Treatment scoring model: long-term follow-up experience at a single institute
.
Int J Urol
.
2015
;
22
(
6
):
541
7
. .
50.
Tully
KH
,
Roghmann
F
,
Noldus
J
,
Chen
X
,
Häuser
L
,
Kibel
AS
, et al
Quantifying the overall survival benefit with early radical cystectomy for patients with histologically confirmed t1 non-muscle-invasive bladder cancer
.
Clin Genitourin Cancer
.
2020
;
S1558-7673
(
20
):
30075
6
.
51.
Chang
SS
,
Boorjian
SA
,
Chou
R
,
Clark
PE
,
Daneshmand
S
,
Konety
BR
, et al
Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline
.
J Urol
.
2016
;
196
(
4
):
1021
9
. .
52.
Turker
P
,
Bostrom
PJ
,
Wroclawski
ML
,
van Rhijn
B
,
Kortekangas
H
,
Kuk
C
, et al
Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome
.
BJU Int
.
2012
;
110
(
6
):
804
11
. .
53.
Willis
D
,
Kamat
AM
.
Nonurothelial bladder cancer and rare variant histologies
.
Hematol Oncol Clin North Am
.
2015
;
29
(
2
):
viii
237
52
. .
54.
Gofrit
ON
,
Yutkin
V
,
Shapiro
A
,
Pizov
G
,
Zorn
KC
,
Hidas
G
, et al
The response of variant histology bladder cancer to intravesical immunotherapy compared to conventional cancer
.
Front Oncol
.
2016
;
6
:
43
. .
55.
Royce
TJ
,
Lin
CC
,
Gray
PJ
,
Shipley
WU
,
Jemal
A
,
Efstathiou
JA
.
Clinical characteristics and outcomes of nonurothelial cell carcinoma of the bladder: results from the National Cancer Data Base
.
Urol Oncol
.
2018
;
36
(
2
):
78
e12
. .
56.
Gilligan
T
,
Dreicer
R
.
The atypical urothelial cancer patient: management of bladder cancers of non-transitional cell histology and cancers of the ureters and renal pelvis
.
Semin Oncol
.
2007
;
34
(
2
):
145
53
. .
57.
Abol-Enein
H
,
Kava
BR
,
Carmack
AJ
.
Nonurothelial cancer of the bladder
.
Urology
.
2007
;
69
(
1 Suppl l
):
93
104
. .
58.
Sui
W
,
Matulay
JT
,
Onyeji
IC
,
Theofanides
MC
,
James
MB
,
RoyChoudhury
A
, et al
Contemporary treatment patterns and outcomes of sarcomatoid bladder cancer
.
World J Urol
.
2017
;
35
(
7
):
1055
61
. .
59.
Mally
AD
,
Tin
AL
,
Lee
JK
,
Satasivam
P
,
Cha
EK
,
Donat
SM
, et al
Clinical outcomes of patients with t1 nested variant of urothelial carcinoma compared to pure urothelial carcinoma of the bladder
.
Clin Genitourin Cancer
.
2017
;
S1558-7673
(
17
):
30199
4
. .
60.
Spaliviero
M
,
Dalbagni
G
,
Bochner
BH
,
Poon
BY
,
Huang
H
,
Al-Ahmadie
HA
, et al
Clinical outcome of patients with T1 micropapillary urothelial carcinoma of the bladder
.
J Urol
.
2014
;
192
(
3
):
702
7
. .
61.
Diamantopoulos
LN
,
Khaki
AR
,
Grivas
P
,
Gore
JL
,
Schade
GR
,
Hsieh
AC
, et al
Plasmacytoid urothelial carcinoma: response to chemotherapy and oncologic outcomes
.
Bladder Cancer
.
2020
;
6
(
1
):
71
81
. .
62.
Stroman
L
,
Nair
R
,
Russell
B
,
Malik
N
,
Desai
A
,
Chandra
A
, et al
The impact of non-urothelial variant histology on oncological outcomes following radical cystectomy
.
BJU Int
.
2019
;
124
(
3
):
418
23
. .
63.
Mannas
MP
,
Lee
T
,
Nykopp
TK
,
Batista da Costa
J
,
Black
PC
.
A risk-stratified approach to the management of high-grade T1 bladder cancer
.
Curr Opin Urol
.
2018
;
28
(
6
):
563
9
. .
64.
Seisen
T
,
Compérat
E
,
Léon
P
,
Roupret
M
.
Impact of histological variants on the outcomes of nonmuscle invasive bladder cancer after transurethral resection
.
Curr Opin Urol
.
2014
;
24
(
5
):
524
31
. .
65.
Cambier
S
,
Sylvester
RJ
,
Collette
L
,
Gontero
P
,
Brausi
MA
,
van Andel
G
, et al
EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1–3 years of maintenance Bacillus Calmette-Guérin
.
Eur Urol
.
2016
;
69
(
1
):
60
9
. .
66.
Fernandez-Gomez
J
,
Madero
R
,
Solsona
E
,
Unda
M
,
Martinez-Piñeiro
L
,
Gonzalez
M
, et al
Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model
.
J Urol
.
2009
;
182
(
5
):
2195
203
. .
67.
Xylinas
E
,
Kent
M
,
Kluth
L
,
Pycha
A
,
Comploj
E
,
Svatek
RS
, et al
Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder
.
Br J Cancer
.
2013
;
109
(
6
):
1460
6
. .
68.
Mari
A
,
Kimura
S
,
Foerster
B
,
Abufaraj
M
,
D'Andrea
D
,
Hassler
M
, et al
A systematic review and meta-analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens
.
BJU Int
.
2019
;
123
(
1
):
11
21
. .
69.
Faba
ÓR
,
Pisano
F
,
Krajewski
W
,
Breda
A
,
Palou
J
.
Salvage therapies for non-muscle-invasive bladder cancer: who will respond to Bacillus Calmette-Guérin? Predictors and nomograms
.
Urol Clin North Am
.
2020
;
47
(
1
):
5
13
.
70.
D’Andrea
D
,
Abufaraj
M
,
Susani
M
,
Ristl
R
,
Foerster
B
,
Kimura
S
, et al
Accurate prediction of progression to muscle-invasive disease in patients with pT1G3 bladder cancer: a clinical decision-making tool
.
Urol Oncol
.
2018
;
36
(
5
):
239.e1
7
.
71.
Metcalfe
MJ
,
Ferguson
JE
,
Li
R
,
Xiao
L
,
Guo
CC
,
Czerniak
BA
, et al
Impact of high-risk features and effect of neoadjuvant chemotherapy in urothelial cancer patients with invasion into the lamina propria on transurethral resection in the absence of deep muscle invasion
.
Eur Urol Focus
.
2017
;
3
(
6
):
577
83
. .
72.
Kim
HS
,
Jeong
CW
,
Kwak
C
,
Kim
HH
,
Ku
JH
.
Novel nomograms to predict recurrence and progression in primary non-muscle-invasive bladder cancer: validation of predictive efficacy in comparison with European Organization of Research and Treatment of Cancer scoring system
.
World J Urol
.
2019
;
37
(
9
):
1867
77
. .
73.
Fujita
N
,
Hatakeyama
S
,
Momota
M
,
Tobisawa
Y
,
Yoneyama
T
,
Yamamoto
H
, et al
Impact of substratification on predicting oncological outcomes in patients with primary high-risk non-muscle-invasive bladder cancer who underwent transurethral resection of bladder tumor
.
Urol Oncol
.
2020
;
38
(
10
):
795
e17
. .
74.
Ma
B
,
Li
Y
,
Han
S
,
Jiang
X
,
Zhao
Y
,
Guo
J
, et al
Radical cystectomy for pT1 urothelial carcinoma of bladder not amenable to TURBT: Long-term results
.
Eur J Surg Oncol
.
2019
;
45
(
10
):
1993
9
. .
75.
Suh
J
,
Moon
KC
,
Jung
JH
,
Lee
J
,
Song
WH
,
Kang
YJ
, et al
BCG instillation versus radical cystectomy for high-risk NMIBC with squamous/glandular histologic variants
.
Sci Rep
.
2019
;
9
(
1
):
15268
. .
76.
Fujii
N
,
Hoshii
Y
,
Hirata
H
,
Mori
J
,
Shimizu
K
,
Kobayashi
K
, et al
Impact of divergent differentiation in urothelial carcinoma on oncological outcome in patients with T1 high-grade bladder cancer
.
Jpn J Clin Oncol
.
2017
;
47
(
6
):
560
7
. .
77.
Prado
K
,
Greenberg
D
,
Zhang
C
,
Sun
A
,
Skinner
E
.
Management of variant histology in non-muscle invasive bladder cancer
.
J Urol
.
2020
;
203
(
4S
):
e263
.
78.
Witjes
JA
,
Babjuk
M
,
Bellmunt
J
,
Bruins
HM
,
De Reijke
TM
,
De Santis
M
, et al
EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer – an international collaborative multistakeholder effort: under the auspices of the EAU-ESMO Guidelines Committees
.
Eur Urol
.
2020
;
77
(
2
):
223
50
.
79.
Amin
MB
.
Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications
.
Mod Pathol
.
2009
;
22
(
Suppl 2
):
S96
118
. .
80.
Kim
SP
,
Frank
I
,
Cheville
JC
,
Thompson
RH
,
Weight
CJ
,
Thapa
P
, et al
The impact of squamous and glandular differentiation on survival after radical cystectomy for urothelial carcinoma
.
J Urol
.
2012
;
188
(
2
):
405
9
. .
81.
Ehdaie
B
,
Maschino
A
,
Shariat
SF
,
Rioja
J
,
Hamilton
RJ
,
Lowrance
WT
, et al
Comparative outcomes of pure squamous cell carcinoma and urothelial carcinoma with squamous differentiation in patients treated with radical cystectomy
.
J Urol
.
2012
;
187
(
1
):
74
9
. .
82.
Antunes
AA
,
Nesrallah
LJ
,
Dall'Oglio
MF
,
Maluf
CE
,
Camara
C
,
Leite
KR
, et al
The role of squamous differentiation in patients with transitional cell carcinoma of the bladder treated with radical cystectomy
.
Int Braz J Urol
.
2007
;
33
(
3
):
339
46
. .
83.
Kastritis
E
,
Dimopoulos
MA
,
Antoniou
N
,
Deliveliotis
C
,
Chrisofos
M
,
Skolarikos
A
, et al
The outcome of patients with advanced pure squamous or mixed squamous and transitional urothelial carcinomas following platinum-based chemotherapy
.
Anticancer Res
.
2006
;
26
(
5B
):
3865
9
.
84.
Scosyrev
E
,
Ely
BW
,
Messing
EM
,
Speights
VO
,
Grossman
HB
,
Wood
DP
, et al
Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710)
.
BJU Int
.
2011
;
108
(
5
):
693
9
. .
85.
Xu
H
,
Xie
L
,
Liu
X
,
Zhang
Y
,
Shen
Z
,
Chen
T
, et al
Impact of squamous and/or glandular differentiation on recurrence and progression following transurethral resection for non-muscle invasive urothelial carcinoma of bladder
.
Oncol Lett
.
2017
;
14
(
3
):
3522
8
. .
86.
Yorozuya
W
,
Nishiyama
N
,
Shindo
T
,
Kyoda
Y
,
Itoh
N
,
Sugita
S
, et al
Bacillus Calmette-Guérin may have clinical benefit for glandular or squamous differentiation in non-muscle invasive bladder cancer patients: retrospective multicenter study
.
Jpn J Clin Oncol
.
2018
;
48
(
7
):
661
6
.
87.
Gaisa
NT
,
Braunschweig
T
,
Reimer
N
,
Bornemann
J
,
Eltze
E
,
Siegert
S
, et al
Different immunohistochemical and ultrastructural phenotypes of squamous differentiation in bladder cancer
.
Virchows Arch
.
2011
;
458
(
3
):
301
12
. .
88.
Hovelson
DH
,
Udager
AM
,
McDaniel
AS
,
Grivas
P
,
Palmbos
P
,
Tamura
S
, et al
Targeted DNA and RNA sequencing of paired urothelial and squamous bladder cancers reveals discordant genomic and transcriptomic events and unique therapeutic implications
.
Eur Urol
.
2018
;
74
(
6
):
741
53
. .
89.
Blochin
EB
,
Park
KJ
,
Tickoo
SK
,
Reuter
VE
,
Al-Ahmadie
H
.
Urothelial carcinoma with prominent squamous differentiation in the setting of neurogenic bladder: role of human papillomavirus infection
.
Mod Pathol
.
2012
;
25
(
11
):
1534
42
. .
90.
Chapman-Fredricks
JR
,
Cioffi-Lavina
M
,
Accola
MA
,
Rehrauer
WM
,
Garcia-Buitrago
MT
,
Gomez-Fernandez
C
, et al
High-risk human papillomavirus DNA detected in primary squamous cell carcinoma of urinary bladder
.
Arch Pathol Lab Med
.
2013
;
137
(
8
):
1088
93
. .
91.
Warrick
JI
.
Clinical significance of histologic variants of bladder cancer
.
J Natl Compr Canc Netw
.
2017
;
15
(
10
):
1268
74
. .
92.
Honma
I
,
Masumori
N
,
Sato
E
,
Takayanagi
A
,
Takahashi
A
,
Itoh
N
, et al
Local recurrence after radical cystectomy for invasive bladder cancer: an analysis of predictive factors
.
Urology
.
2004
;
64
(
4
):
744
8
. .
93.
Gluck
G
,
Hortopan
M
,
Stănculeanu
D
,
Chiriță
M
,
Stoica
R
,
Sinescu
I
.
Comparative study of conventional urothelial carcinoma, squamous differentiation carcinoma and pure squamous carcinoma in patients with invasive bladder tumors
.
J Med Life
.
2014
;
7
(
2
):
211
4
.
94.
Lopez-Beltran
A
,
Requena
MJ
,
Alvarez-Kindelan
J
,
Quintero
A
,
Blanca
A
,
Montironi
R
.
Squamous differentiation in primary urothelial carcinoma of the urinary tract as seen by MAC387 immunohistochemistry
.
J Clin Pathol
.
2007
;
60
(
3
):
332
5
. .
95.
Raman
JD
,
Jafri
SM
.
Surgical management of bladder urothelial carcinoma with squamous differentiation
.
Urol Oncol
.
2015
;
33
(
10
):
429
33
. .
96.
Li
G
,
Hu
J
,
Niu
Y
.
Squamous differentiation in pT1 bladder urothelial carcinoma predicts poor response for intravesical chemotherapy
.
Oncotarget
.
2018
;
9
(
1
):
217
23
. .
97.
Li
G
,
Song
H
,
Wang
J
,
Bao
Y
,
Niu
Y
.
Poor prognostic value of lymphovascular invasion for pT1 urothelial carcinoma with squamous differentiation in bladder cancer
.
Sci Rep
.
2016
;
6
:
27586
. .
98.
Solomon
JP
,
Lowenthal
BM
,
Kader
AK
,
Parsons
JK
,
Flaig
TW
,
Siefker-Radtke
AO
, et al
Challenges in the diagnosis of urothelial carcinoma variants: can emerging molecular data complement pathology review?
Urology
.
2017
;
102
:
7
16
. .
99.
Lim
M
,
Adsay
NV
,
Grignon
D
,
Osunkoya
AO
.
Urothelial carcinoma with villoglandular differentiation: a study of 14 cases
.
Mod Pathol
.
2009
;
22
(
10
):
1280
6
. .
100.
Miller
JS
,
Epstein
JI
.
Noninvasive urothelial carcinoma of the bladder with glandular differentiation: report of 24 cases
.
Am J Surg Pathol
.
2009
;
33
(
8
):
1241
8
. .
101.
Sanguedolce
F
,
Landriscina
M
,
Ambrosi
A
,
Tartaglia
N
,
Cianci
P
,
Di Millo
M
, et al
Bladder metastases from breast cancer: managing the unexpected. A systematic review
.
Urol Int
.
2018
;
101
(
2
):
125
31
. .
102.
Sanguedolce
F
,
Loizzi
D
,
Sollitto
F
,
Di Bisceglie
M
,
Lucarelli
G
,
Carrieri
G
, et al
Bladder metastases from lung cancer: clinical and pathological implications: a systematic review
.
Oncology
.
2017
;
92
(
3
):
125
34
. .
103.
Cormio
L
,
Sanguedolce
F
,
Di Fino
G
,
Massenio
P
,
Liuzzi
G
,
Bufo
P
, et al
Bladder metastasis from lung adenocarcinoma: a difficult differential diagnosis with primary bladder adenocarcinoma
.
World J Surg Oncol
.
2014
;
12
:
90
. .
104.
Vail
E
,
Zheng
X
,
Zhou
M
,
Yang
X
,
Fallon
JT
,
Epstein
JI
, et al
Telomerase reverse transcriptase promoter mutations in glandular lesions of the urinary bladder
.
Ann Diagn Pathol
.
2015
;
19
(
5
):
301
5
. .
105.
Zhao
G
,
Wang
C
,
Tang
Y
,
Liu
X
,
Liu
Z
,
Li
G
, et al
Glandular differentiation in pT1 urothelial carcinoma of bladder predicts poor prognosis
.
Sci Rep
.
2019
;
9
(
1
):
5323
. .
106.
Sanguedolce
F
,
Cormio
A
,
Calò
B
,
Landriscina
M
,
Carvalho-Dias
E
,
Cormio
L
.
Micropapillary bladder cancer, a variant histology of the elderly
.
JGG
.
2018
;
66
:
222
7
.
107.
Sanguedolce
F
,
Russo
D
,
Mancini
V
,
Selvaggio
O
,
Calo
B
,
Carrieri
G
, et al
Prognostic and therapeutic role of HER2 expression in micropapillary carcinoma of the bladder
.
Mol Clin Oncol
.
2019
;
10
(
2
):
205
13
. .
108.
Guo
CC
,
Dadhania
V
,
Zhang
L
,
Majewski
T
,
Bondaruk
J
,
Sykulski
M
, et al
Gene expression profile of the clinically aggressive micropapillary variant of bladder cancer
.
Eur Urol
.
2016
;
70
(
4
):
611
20
. .
109.
Sui
W
,
Matulay
JT
,
James
MB
,
Onyeji
IC
,
Theofanides
MC
,
RoyChoudhury
A
, et al
Micropapillary bladder cancer: insights from the National Cancer Database
.
Bladder Cancer
.
2016
;
2
(
4
):
415
23
. .
110.
Abufaraj
M
,
Foerster
B
,
Schernhammer
E
,
Moschini
M
,
Kimura
S
,
Hassler
MR
, et al
Micropapillary urothelial carcinoma of the bladder: a systematic review and meta-analysis of disease characteristics and treatment outcomes
.
Eur Urol
.
2019
;
75
(
4
):
649
58
. .
111.
Compérat
E
,
Roupret
M
,
Yaxley
J
,
Reynolds
J
,
Varinot
J
,
Ouzaïd
I
, et al
Micropapillary urothelial carcinoma of the urinary bladder: a clinicopathological analysis of 72 cases
.
Pathology
.
2010
;
42
(
7
):
650
4
. .
112.
Lopez-Beltran
A
,
Henriques
V
,
Montironi
R
,
Cimadamore
A
,
Raspollini
MR
,
Cheng
L
.
Variants and new entities of bladder cancer
.
Histopathology
.
2019
;
74
(
1
):
77
96
. .
113.
Lopez-Beltran
A
,
Montironi
R
,
Blanca
A
,
Cheng
L
.
Invasive micropapillary urothelial carcinoma of the bladder
.
Hum Pathol
.
2010
;
41
(
8
):
1159
64
. .
114.
Wang
JK
,
Boorjian
SA
,
Cheville
JC
,
Kim
SP
,
Tarrell
RF
,
Thapa
P
, et al
Outcomes following radical cystectomy for micropapillary bladder cancer versus pure urothelial carcinoma: a matched cohort analysis
.
World J Urol
.
2012
;
30
(
6
):
801
6
. .
115.
Samaratunga
H
,
Khoo
K
.
Micropapillary variant of urothelial carcinoma of the urinary bladder; a clinicopathological and immunohistochemical study
.
Histopathology
.
2004
;
45
(
1
):
55
64
. .
116.
Sangoi
AR
,
Beck
AH
,
Amin
MB
,
Cheng
L
,
Epstein
JI
,
Hansel
DE
, et al
Interobserver reproducibility in the diagnosis of invasive micropapillary carcinoma of the urinary tract among urologic pathologists
.
Am J Surg Pathol
.
2010
;
34
(
9
):
1367
76
. .
117.
Amin
A
,
Epstein
JI
.
Noninvasive micropapillary urothelial carcinoma: a clinicopathologic study of 18 cases
.
Hum Pathol
.
2012
;
43
(
12
):
2124
8
. .
118.
Jackson
BL
,
Mohammed
A
,
Mayer
N
,
Dormer
J
,
Griffiths
TR
.
Is immediate radical cystectomy necessary for all patients with non-muscle-invasive micropapillary bladder cancer?
Urol Int
.
2016
;
96
(
1
):
32
8
. .
119.
Sangoi
AR
,
Cox
RM
,
Higgins
JP
,
Quick
CM
,
McKenney
JK
.
Non-invasive papillary urothelial carcinoma with “micropapillary” architecture: clinicopathologic study of 18 patients emphasizing clinical outcomes
.
Histopathology
.
2020
. Epub ahead of print.
120.
Vourganti
S
,
Harbin
A
,
Singer
EA
,
Shuch
B
,
Metwalli
AR
,
Agarwal
PK
.
Low grade micropapillary urothelial carcinoma, does it exist? – Analysis of management and outcomes from the Surveillance, Epidemiology and End Results (SEER) database
.
J Cancer
.
2013
;
4
(
4
):
336
42
. .
121.
Ghoneim
IA
,
Miocinovic
R
,
Stephenson
AJ
,
Garcia
JA
,
Gong
MC
,
Campbell
SC
, et al
Neoadjuvant systemic therapy or early cystectomy? Single-center analysis of outcomes after therapy for patients with clinically localized micropapillary urothelial carcinoma of the bladder
.
Urology
.
2011
;
77
(
4
):
867
70
. .
122.
Gaya
JM
,
Palou
J
,
Algaba
F
,
Arce
J
,
Rodríguez-Faba
O
,
Villavicencio
H
.
The case for conservative management in the treatment of patients with non-muscle-invasive micropapillary bladder carcinoma without carcinoma in situ
.
Can J Urol
.
2010
;
17
(
5
):
5370
6
.
123.
Martin-Doyle
W
,
Leow
JJ
,
Orsola
A
,
Chang
SL
,
Bellmunt
J
.
Improving selection criteria for early cystectomy in high-grade t1 bladder cancer: a meta-analysis of 15,215 patients
.
J Clin Oncol
.
2015
;
33
(
6
):
643
50
. .
124.
Fernández
MI
,
Williams
SB
,
Willis
DL
,
Slack
RS
,
Dickstein
RJ
,
Parikh
S
, et al
Clinical risk stratification in patients with surgically resectable micropapillary bladder cancer
.
BJU Int
.
2017
;
119
(
5
):
684
91
. .
125.
Williams
SB
,
Kamat
AM
.
Optimum management of non-muscle-invasive micropapillary variant urothelial carcinoma: possibility for missed chance of cure?
BJU Int
.
2016
;
118
(
3
):
349
50
. .
126.
Willis
DL
,
Flaig
TW
,
Hansel
DE
,
Milowsky
MI
,
Grubb
RL
,
Al-Ahmadie
HA
, et al
Micropapillary bladder cancer: current treatment patterns and review of the literature
.
Urol Oncol
.
2014
;
32
(
6
):
826
32
. .
127.
Lopez-Beltran
A
,
Pacelli
A
,
Rothenberg
HJ
,
Wollan
PC
,
Zincke
H
,
Blute
ML
, et al
Carcinosarcoma and sarcomatoid carcinoma of the bladder: clinicopathological study of 41 cases
.
J Urol
.
1998
;
159
(
5
):
1497
503
. .
128.
Sanfrancesco
J
,
McKenney
JK
,
Leivo
MZ
,
Gupta
S
,
Elson
P
,
Hansel
DE
.
Sarcomatoid urothelial carcinoma of the bladder: analysis of 28 cases with emphasis on clinicopathologic features and markers of epithelial-to-mesenchymal transition
.
Arch Pathol Lab Med
.
2016
;
140
(
6
):
543
51
. .
129.
Sung
MT
,
Wang
M
,
MacLennan
GT
,
Eble
JN
,
Tan
PH
,
Lopez-Beltran
A
, et al
Histogenesis of sarcomatoid urothelial carcinoma of the urinary bladder: evidence for a common clonal origin with divergent differentiation
.
J Pathol
.
2007
;
211
(
4
):
420
30
. .
130.
Bansal
A
,
Kumar
N
,
Sharma
SC
.
Sarcomatoid variant of urothelial carcinoma of the urinary bladder
.
J Cancer Res Ther
.
2013
;
9
(
4
):
571
3
. .
131.
Fatima
N
,
Canter
DJ
,
Carthon
BC
,
Kucuk
O
,
Master
VA
,
Nieh
PT
, et al
Sarcomatoid urothelial carcinoma of the bladder: a contemporary clinicopathologic analysis of 37 cases
.
Can J Urol
.
2015
;
22
(
3
):
7783
7
.
132.
Wang
J
,
Wang
FW
,
Lagrange
CA
,
Hemstreet Iii
GP
,
Kessinger
A
.
Clinical features of sarcomatoid carcinoma (carcinosarcoma) of the urinary bladder: analysis of 221 cases
.
Sarcoma
.
2010
;
2010
:
454792
.
133.
Processali
T
,
Diminutto
A
,
Cerruto
MA
,
Antonelli
A
.
The impact of histological variants on bladder cancer outcomes
.
AME Med J
.
2020
;
5
:
4
. .
134.
Black
PC
,
Brown
GA
,
Dinney
CP
.
Clinical and therapeutic significance of aberrant differentiation patterns in bladder cancer
.
Expert Rev Anticancer Ther
.
2007
;
7
(
7
):
1015
26
. .
135.
Al-Ahmadie
HA
,
Iyer
G
,
Lee
BH
,
Scott
SN
,
Mehra
R
,
Bagrodia
A
, et al
Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer
.
Nat Genet
.
2016
;
48
(
4
):
356
8
. .
136.
Monn
MF
,
Kaimakliotis
HZ
,
Pedrosa
JA
,
Cary
KC
,
Bihrle
R
,
Cheng
L
, et al
Contemporary bladder cancer: variant histology may be a significant driver of disease
.
Urol Oncol
.
2015
;
33
(
1
):
18
e20
. .
137.
Dayyani
F
,
Czerniak
BA
,
Sircar
K
,
Munsell
MF
,
Millikan
RE
,
Dinney
CP
, et al
Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis
.
J Urol
.
2013
;
189
(
5
):
1656
61
. .
138.
Kaimakliotis
HZ
,
Monn
MF
,
Cheng
L
,
Masterson
TA
,
Cary
KC
,
Pedrosa
JA
, et al
Plasmacytoid bladder cancer: variant histology with aggressive behavior and a new mode of invasion along fascial planes
.
Urology
.
2014
;
83
(
5
):
1112
6
. .
139.
Raspollini
MR
,
Sardi
I
,
Giunti
L
,
Di Lollo
S
,
Baroni
G
,
Stomaci
N
, et al
Plasmacytoid urothelial carcinoma of the urinary bladder: clinicopathologic, immunohistochemical, ultrastructural, and molecular analysis of a case series
.
Hum Pathol
.
2011
;
42
(
8
):
1149
58
. .
140.
Kawahara
T
,
Oshiro
H
,
Sekiguchi
Z
,
Ito
H
,
Makiyama
K
,
Uemura
H
, et al
High-grade invasive urothelial carcinoma with focal plasmacytoid differentiation successfully treated by transurethral resection followed by chemoradiotherapy
.
Int J Urol
.
2011
;
18
(
12
):
851
3
. .
141.
Kaimakliotis
HZ
,
Monn
MF
,
Cary
KC
,
Pedrosa
JA
,
Rice
K
,
Masterson
TA
, et al
Plasmacytoid variant urothelial bladder cancer: is it time to update the treatment paradigm?
Urol Oncol
.
2014
;
32
(
6
):
833
8
. .
142.
Sood
S
,
Paner
GP
.
Plasmacytoid urothelial carcinoma: an unusual variant that warrants aggressive management and critical distinction on transurethral resections
.
Arch Pathol Lab Med
.
2019
;
143
(
12
):
1562
7
. .
143.
Zhong
M
,
Tian
W
,
Zhuge
J
,
Zheng
X
,
Huang
T
,
Cai
D
, et al
Distinguishing nested variants of urothelial carcinoma from benign mimickers by TERT promoter mutation
.
Am J Surg Pathol
.
2015
;
39
(
1
):
127
31
. .
144.
Weyerer
V
,
Weisser
R
,
Moskalev
EA
,
Haller
F
,
Stoehr
R
,
Eckstein
M
, et al
Distinct genetic alterations and luminal molecular subtype in nested variant of urothelial carcinoma
.
Histopathology
.
2019
;
75
(
6
):
865
75
. .
145.
Wasco
MJ
,
Daignault
S
,
Bradley
D
,
Shah
RB
.
Nested variant of urothelial carcinoma: a clinicopathologic and immunohistochemical study of 30 pure and mixed cases
.
Hum Pathol
.
2010
;
41
(
2
):
163
71
. .
146.
Beltran
AL
,
Cheng
L
,
Montironi
R
,
Blanca
A
,
Leva
M
,
Rouprêt
M
, et al
Clinicopathological characteristics and outcome of nested carcinoma of the urinary bladder
.
Virchows Arch
.
2014
;
465
(
2
):
199
205
. .
147.
Linder
BJ
,
Frank
I
,
Cheville
JC
,
Thompson
RH
,
Thapa
P
,
Tarrell
RF
, et al
Outcomes following radical cystectomy for nested variant of urothelial carcinoma: a matched cohort analysis
.
J Urol
.
2013
;
189
(
5
):
1670
5
. .
148.
Sanguedolce
F
,
Bufo
P
,
Carrieri
G
,
Cormio
L
.
Predictive markers in bladder cancer: do we have molecular markers ready for clinical use?
Crit Rev Clin Lab Sci
.
2014
;
51
(
5
):
291
304
. .
149.
Sanguedolce
F
,
Cormio
A
,
Bufo
P
,
Carrieri
G
,
Cormio
L
.
Molecular markers in bladder cancer: novel research frontiers
.
Crit Rev Clin Lab Sci
.
2015
;
52
(
5
):
242
55
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.